Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 ...

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...

One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

Isomorphic Labs, a drug discovery company spun out of Google DeepMind, is about to make a historic breakthrough in medicine. The company is gearing up to begin human clinical trials for drugs designed ...

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in ...

Google DeepMind's Isomorphic Labs is set to begin human trials of drugs designed by artificial intelligence, marking a ...

As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech hub of Cambridge.

Isomorphic Labs sets up U.S. presence, with an eye on clinical trials. The Alphabet company, spun off from DeepMind, is hiring a new chief medical officer and adding an office in Cambridge.

Isomorphic Labs, together with Google DeepMind, developed and released AlphaFold 3 in May 2024, a revolutionary AI model that can predict the structure and interactions of all of life's molecules ...

About Isomorphic Labs. Isomorphic Labs was founded in 2021, with a mission to transform drug discovery with the power of artificial intelligence, ushering in a new era of biomedical breakthroughs.

About Isomorphic Labs. Isomorphic Labs was founded in 2021, with a mission to transform drug discovery with the power of artificial intelligence, ushering in a new era of biomedical breakthroughs.